Analysts: Yum May be Struggling in China and 3 Other Research Notes to Look Over
Yum! Brands (NYSE:YUM): Buckingham says that August Yum China comps declined to 10 percent versus the consensus of 8 percent. The firm maintains its below consensus third quarter EPS estimate of $0.92 versus the consensus $0.94 estimate and lowered its price target to $76 from $78. The shares are Neutral rated.
Isis Pharmaceuticals (NASDAQ:ISIS): Piper Jaffray views Isis Pharmaceuticals’ fourth collaboration with Biogen (NASDAQ:BIIB) as further evidence of the company’s “willingness to give away economics for its research and drugs to partners.” Piper thinks that shares of Isis should be up only $0.90 on today’s collaboration announcement and reiterates an Underweight rating on the stock. The firm raised its price target for the shares to $20 from $19.
Comerica (NYSE:CMA): Wells Fargo notes that, in presentation slides late Friday, Comerica disclosed that average loan balances have declined by $0.7 billion, or 1.6 percent quarter-to-date, through August 31. Wells says that the loan portfolio shrinking is significantly worse than industry trends would suggest and likely to pressure Comerica’s net interest margin and earnings in the third quarter. The firm reiterates an Underperform rating on the stock.
Cimarex Energy (NYSE:XEC): Morgan Stanley upgraded Cimarex Energy to Overweight from Equal Weight. The firm says that Cimarex trades at the lowest multiple in the group with little credit for the Wolfcamp asset potential. The firm updated its production forecasts and estimates and raised its price target on the shares to $105.
Don’t Miss: Smithfield Deal Gets Federal Brand of Approval.